Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Jenkins

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2017
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of OsimertinibSuzanne Jenkins, James Chih-Hsin Yang, Pasi A Jänne, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2017
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung CancerSuzanne Jenkins, James C-H Yang, Suresh S Ramalingam, et al.
Targeted Oncology|June 6, 2023
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid TumorsTodd M Bauer, Kathleen N Moore, Janet S Rader, et al.
Cancer|November 27, 2019
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancerVassiliki A Papadimitrakopoulou, Ji-Youn Han, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung CancerJhanelle E Gray, Isamu Okamoto, Virote Sriuranpong, et al.
Lancet (London, England)|January 24, 2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trialStephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2017
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of OsimertinibSuzanne Jenkins, James Chih-Hsin Yang, Pasi A Jänne, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 22, 2017
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung CancerSuzanne Jenkins, James C-H Yang, Suresh S Ramalingam, et al.
Targeted Oncology|June 6, 2023
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid TumorsTodd M Bauer, Kathleen N Moore, Janet S Rader, et al.
Cancer|November 27, 2019
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancerVassiliki A Papadimitrakopoulou, Ji-Youn Han, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung CancerJhanelle E Gray, Isamu Okamoto, Virote Sriuranpong, et al.
Lancet (London, England)|January 24, 2021
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trialStephanie Lheureux, Mihaela C Cristea, Jeffrey P Bruce, et al.
Pageof 2